J Clin Oncol 25: 4315-6, 2007
Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled trial
Focusing on whole foods and consistent, balanced habits supports your bodys ability to regulate natural GLP-1 and other key metabolic hormones
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
The process starts with a brief medical consultation, typically completed online within 2448 hours
